Abstract 269P
Background
The enzyme catechol-O-methyltransferase (COMT) inhibits the prognosis of prostate cancer (PCa). There has been no biomarker that aids in the selection of a therapeutic agent among new-generation androgen receptor-axis targeted (ARAT) therapy, such as abiraterone (ABI) or enzalutamide (ENZ). Therefore, we aimed to assess the possibility of using COMT expression as a biomarker for PCa progression and the criteria for selecting ABI or ENZ.
Methods
We retrospectively evaluated 60 patients with PCa treated with ABI or ENZ via needle biopsy or radical prostatectomy at Iwate Medical University. Immunostaining of COMT was performed using formalin-fixed, paraffin-embedded blocks obtained from the initial prostate biopsy for diagnosis or prostatectomy. Immunostaining evaluations were scored by immunostaining intensity (0–3) and staining area (0–3) and the score ≥4 was defined as “high expression” and the score <4 was defined as “low expression.” The associations between COMT expression levels and clinical outcomes, including the duration of ENZ or ABI response, were also assessed.
Results
Of the 60 cases, nine (15%) showed low expression. Overall survival (OS) was significantly shorter in patients with lower COMT expression (hazard ratio [HR] = 0.24, 95% confidence interval [CI] 0.07–0.83, P= 0.024). When ENZ was administered as the first ARAT, progression-free survival (PFS) was significantly different between patients with COMT expression scores <4 and ≥4 (median 5.9 and 23.3 months, respectively). However, when the patients were administered ABI as the first ARAT, the PFS of the patients who underwent ARAT therapy showed no significant difference between COMT expression scores <4 and ≥4.
Conclusions
Patients with lower COMT expression have a significantly poorer prognosis for PCa. In addition, the post-ENZ administration PFS, as the first ARAT, correlated with COMT expression levels. This study is the first report on an association between COMT expression levels and the duration of ARAT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract